EUCTR2013-005588-24-CZ进行中（未招募）1 期
AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 1 (AMPACT1) – an open-label extension to the TACTT2 study - AMPACT1
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 330
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •A subject will be eligible for this study if all of the following criteria apply:
- •1. Attendance of the final visit FUV3 of study AM 101-CL-12-01 (TACTT2);
- •TV1 of AMPACT1 should preferably be conducted within 48 hours of FUV3 of TACTT2, but no later than 14 days thereafter.
- •2. Negative urine pregnancy test for women of childbearing potential;
- •3. Willing and able to attend the study visits during at least one treatment cycle;
- •4. Able to read and understand study documents, to complete the relevant questionnaires and rating scales and follow Investigator instructions;
- •5. Able to understand and follow study personnel instructions during audiologic measurements;
- •6. Willing and able to use adequate hearing protection, respectively to refrain from engaging in activities or work involving loud noise exposure where sufficient hearing protection is not possible or ensured;
- •7. Willing and able to protect ear canal and middle ear from water exposure as long as tympanic membrane is not fully closed after IMP administration;
- •8. Signed IRB/REB/IEC approved Informed Consent Form (ICF).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 45
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •A subject will not be eligible for this study if any of the following criteria apply:
- •1. Study drug related or procedure related adverse event leading to treatment discontinuation in study AM 101-CL-12-01 (TACTT2);
- •2. Suspected or diagnosed Meniere’s Disease, endolymphatic hydrops, acoustic neuroma or history of fluctuating hearing loss;
- •3. Ongoing purulent acute or chronic otitis media or otitis externa;
- •4. Abnormality of the tympanic membrane in the affected ear(s) that would preclude i.t. injection;
- •5. Subjects with current hearing loss in the affected ear(s) of 75 dB or more in one or more test frequencies (250 Hz, 500 Hz, 1 kHz, 2 kHz, 3 kHz, 4 kHz, 6 kHz, 8 kHz);
- •6. Any ongoing drug-based therapy for otitis media or otitis externa;
- •7. Any drug-based therapy known as potentially tinnitus-inducing (e.g. aminoglycosides, cisplatin, loop diuretics, high doses of aspirin [>2 g /day] or quinine) in the past 2 weeks prior to enrollment into the open-label study (TV1, D0), or that is ongoing or planned for the study duration;
- •8. Use of any other NMDA receptor antagonist (e.g. memantine, dextromethorphan) that is planned for the study duration;
- •9. Any planned pharmacological or non-pharmacological treatment of tinnitus for the study duration;
- •10. History within the past two years or presence of drug abuse or alcoholism;
- •11. Subjects with diagnosed anxiety disorders, depression, bipolar disorder, schizophrenia or other significant psychiatric diseases requiring current drug treatment or subjects who required treatment in the previous TACTT2 study prior to enrollment into the open-label study (TV1, D0) for these diseases;
- •12. Use of any antidepressant or anti-anxiety medication in the past 2 weeks prior to enrollment into the open-label study (TV1, D0), or that is ongoing, or that is planned for the study duration unless the medication was taken in a low dose and permanently during the previous TACTT2 study prior to enrollment into the open-label study (TV1, D0), not for the treatment of tinnitus, and if the treatment will be maintained throughout the duration of the study;
- •13. Any clinically relevant respiratory, cardiovascular, neurological disorder (except vertigo), as determined by the Investigator;
- •14. Any clinically relevant abnormalities in physical examination on Day 0 (TV1, D0);
- •15. Women who are breast-feeding, pregnant or who are planning to become pregnant during the study;
- •16. Women of childbearing potential who are unwilling or unable to practice contraception, such as hormonal contraceptives, double barrier, sexual abstinence or intercourse with a partner who has been vasectomised for at least three months;
- •17. Involvement or planned involvement in legal action related to the present peripheral tinnitus during the course of the study;
- •18. Concurrent participation in another clinical study.
研究者
相似试验
进行中（未招募）
1 期
Study to observe long-term safety of AM-101 in patients with tinnitusTreatment of peripheral tinnitus following traumatic cochlear injury or otitis mediaMedDRA version: 19.0Level: PTClassification code 10043882Term: TinnitusSystem Organ Class: 10013993 - Ear and labyrinth disordersEUCTR2013-001527-39-PLAuris Medical AG600
进行中（未招募）
1 期
Study to observe long-term safety of AM-101 in patients with tinnitusEUCTR2013-001527-39-HUAuris Medical AG600
进行中（未招募）
1 期
Study to observe long-term safety of AM-101 in patients with tinnitusTreatment of peripheral tinnitus following traumatic cochlear injury or otitis mediaMedDRA version: 17.0Level: PTClassification code 10043882Term: TinnitusSystem Organ Class: 10013993 - Ear and labyrinth disordersEUCTR2013-001527-39-ESAuris Medical AG600
进行中（未招募）
1 期
Study to observe long-term safety of AM-101 in patients with tinnitusEUCTR2013-001527-39-ATAuris Medical AG600
进行中（未招募）
1 期
Study to observe long-term safety of AM-101 in patients with tinnitusEUCTR2013-001527-39-GBAuris Medical AG600